Abstract
A better understanding of human hepatocellular carcinoma (HCC) pathogenesis at the molecular level will facilitate the discovery of tumor-initiating events. Transcriptome sequencing revealed that adenosine-to-inosine (A→I) RNA editing of AZIN1 (encoding antizyme inhibitor 1) is increased in HCC specimens. A→I editing of AZIN1 transcripts, specifically regulated by ADAR1 (encoding adenosine deaminase acting on RNA-1), results in a serine-to-glycine substitution at residue 367 of AZIN1, located in β-strand 15 (β15) and predicted to cause a conformational change, induced a cytoplasmic-to-nuclear translocation and conferred gain-of-function phenotypes that were manifested by augmented tumor-initiating potential and more aggressive behavior. Compared with wild-type AZIN1 protein, the edited form has a stronger affinity to antizyme, and the resultant higher AZIN1 protein stability promotes cell proliferation through the neutralization of antizyme-mediated degradation of ornithine decarboxylase (ODC) and cyclin D1 (CCND1). Collectively, A→I RNA editing of AZIN1 may be a potential driver in the pathogenesis of human cancers, particularly HCC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Accessions
Ensembl
NCBI Reference Sequence
Protein Data Bank
References
Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
Farazi, P.A. & DePinho, R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674–687 (2006).
Thorgeirsson, S.S. & Grisham, J.W. Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet. 31, 339–346 (2002).
Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685–696 (2010).
Morozova, O. & Marra, M.A. Applications of next-generation sequencing technologies in functional genomics. Genomics 92, 255–264 (2008).
Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat. Rev. Genet. 10, 57–63 (2009).
Bass, B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71, 817–846 (2002).
Nishikura, K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 79, 321–349 (2010).
Herb, A., Higuchi, M., Sprengel, R. & Seeburg, P.H. Q/R site editing in kainate receptor GluR5 and GluR6 pre-mRNAs requires distant intronic sequences. Proc. Natl. Acad. Sci. USA 93, 1875–1880 (1996).
Higuchi, M. et al. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 75, 1361–1370 (1993).
Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778–809 (2001).
Farajollahi, S. & Maas, S. Molecular diversity through RNA editing: a balancing act. Trends Genet. 26, 221–230 (2010).
Mangold, U., Hayakawa, H., Coughlin, M., Munger, K. & Zetter, B.R. Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification. Oncogene 27, 604–613 (2008).
Young, M., Kirshenbaum, K., Dill, K.A. & Highsmith, S. Predicting conformational switches in proteins. Protein Sci. 8, 1752–1764 (1999).
Fujita, K., Murakami, Y. & Hayashi, S. A macromolecular inhibitor of the antizyme to ornithine decarboxylase. Biochem. J. 204, 647–652 (1982).
Mangold, U. Antizyme inhibitor: mysterious modulator of cell proliferation. Cell. Mol. Life Sci. 63, 2095–2101 (2006).
Bercovich, Z. & Kahana, C. Degradation of antizyme inhibitor, an ornithine decarboxylase homologous protein, is ubiquitin-dependent and is inhibited by antizyme. J. Biol. Chem. 279, 54097–54102 (2004).
Kahana, C. Antizyme and antizyme inhibitor, a regulatory tango. Cell. Mol. Life Sci. 66, 2479–2488 (2009).
Newman, R.M. et al. Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J. Biol. Chem. 279, 41504–41511 (2004).
Vivanco, I. & Sawyers, C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489–501 (2002).
Morgan, D.O. Principles of CDK regulation. Nature 374, 131–134 (1995).
Pyronnet, S., Pradayrol, L. & Sonenberg, N. A cell cycle–dependent internal ribosome entry site. Mol. Cell 5, 607–616 (2000).
Lukas, J., Petersen, B.O., Holm, K., Bartek, J. & Helin, K. Deregulated expression of E2F family members induces S-phase entry and overcomes p16INK4A-mediated growth suppression. Mol. Cell. Biol. 16, 1047–1057 (1996).
Gommans, W.M., Mullen, S.P. & Maas, S. RNA editing: a driving force for adaptive evolution? Bioessays 31, 1137–1145 (2009).
Mattick, J.S. & Mehler, M.F. RNA editing, DNA recoding and the evolution of human cognition. Trends Neurosci. 31, 227–233 (2008).
Reenan, R.A. Molecular determinants and guided evolution of species-specific RNA editing. Nature 434, 409–413 (2005).
Li, J.B. et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science 324, 1210–1213 (2009).
Shah, S.P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809–813 (2009).
Cenci, C. et al. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 283, 7251–7260 (2008).
Maas, S., Patt, S., Schrey, M. & Rich, A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. USA 98, 14687–14692 (2001).
Paz, N. et al. Altered adenosine-to-inosine RNA editing in human cancer. Genome Res. 17, 1586–1595 (2007).
Gallo, A. & Galardi, S. A-to-I RNA editing and cancer: from pathology to basic science. RNA Biol. 5, 135–139 (2008).
Albeck, S. et al. Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci. 17, 793–802 (2008).
Matsufuji, S. et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 80, 51–60 (1995).
Rom, E. & Kahana, C. Polyamines regulate the expression of ornithine decarboxylase antizyme in vitro by inducing ribosomal frame-shifting. Proc. Natl. Acad. Sci. USA 91, 3959–3963 (1994).
Olsen, R.R. & Zetter, B.R. Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer. Mol. Cancer Res. 9, 1285–1293 (2011).
Hu, L. et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 23, 298–302 (2004).
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
Zweig, A.S., Karolchik, D., Kuhn, R.M., Haussler, D. & Kent, W.J. UCSC genome browser tutorial. Genomics 92, 75–84 (2008).
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511–515 (2010).
Koboldt, D.C. et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283–2285 (2009).
Cao, Z.A., Daniel, D. & Hanahan, D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2, 11 (2002).
Acknowledgements
We thank and acknowledge the patients for tumor tissue donation to our tissue bank and M. Fullwood (Cancer Science Institute of Singapore, National University of Singapore, Singapore) for providing complementary DNA (cDNA) samples of normal tissues. We thank K. Man and C.M. Lo (Department of Surgery, The University of Hong Kong) for providing healthy human liver tissues. This work was supported by Hong Kong Research Grant Council grants, including the Theme-based Research Scheme Fund (T12-403/11) (X.-Y.G.), Collaborative Research Funds (HKBU5/CRF/10, HKU7/CRG/09 and HKU3/CRF/11R) (X.-Y.G.), the General Research Fund (HKU/766811M) (X.-Y.G.), the China National Basic Research Program (2012CB967001) (X.-Y.G.), the 'Hundred Talents Program' at Sun Yat-Sen University (85000-3171311) (X.-Y.G.), the China National Key Science-Technology Special Project of Infectious Diseases (2008ZX10002-022) (X.-Y.G.) and the Singapore Ministry of Health's National Medical Research Council under its Singapore Translational Research (STaR) Investigator Award (D.G.T).
Author information
Authors and Affiliations
Contributions
L.C., Yan Li (Department of Clinical Oncology, The University of Hong Kong, Hong Kong) and X.-Y.G. initiated and designed the study. L.C. wrote the manuscript with input from D.G.T. and X.-Y.G. L.C., Yan Li (Department of Clinical Oncology, The University of Hong Kong, Hong Kong) and C.H.L. designed the experiments and interpreted the results. L.C. and Yan Li (Department of Clinical Oncology, The University of Hong Kong, Hong Kong) performed all experiments with assistance from T.H.M.C., Y.S., M.L., L.Q. and R.K.K.C. Illumina mRNA library preparation was performed by N.Z. and A.H.Y.T. C.H.L. and S.L. performed all bioinformatics analyses of transcriptome sequencing. HCC clinical samples and the relevant clinical information were provided by Y.-F.Y. and extracted by L.C. and Yan Li (State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, China). Healthy human liver tissues were provided by K.M. and C.M.L. Human PBMCs were collected by L.F. NPC samples were provided and extracted by D.L.-W.K., K.L.K. and L.C. D.G.T. and X.-Y.G. supervised the project.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Data, Supplementary Figures 1–7 and Supplementary Tables 1–6 (PDF 3200 kb)
Rights and permissions
About this article
Cite this article
Chen, L., Li, Y., Lin, C. et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat Med 19, 209–216 (2013). https://doi.org/10.1038/nm.3043
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3043
This article is cited by
-
Antizyme inhibitor family: biological and translational research implications
Cell Communication and Signaling (2024)
-
The role of ADAR1 through and beyond its editing activity in cancer
Cell Communication and Signaling (2024)
-
RNA modification: mechanisms and therapeutic targets
Molecular Biomedicine (2023)
-
Changes in ADAR RNA editing patterns in CMV and ZIKV congenital infections
BMC Genomics (2023)
-
Emerging role of the RNA-editing enzyme ADAR1 in stem cell fate and function
Biomarker Research (2023)